Alvaro

Médico - UTP
Grupo de Investigación Infección e Inmunidad UTP
Grupo de Investigación Salud pública y enfermedades infecciosas

[Dr Kamlesh Darji @DrKamleshDarji1]

Topic 66 : Haemophilia A vs. Haemophilia B vs. Von Willebrand disease (vWD) - 66/100 #NEETPG

[Benlazar S M A @smbenlazar]

Hodgkin lymphoma: EHA Clinical Practice Guidelines for diagnosis, treatment, and follow-up https://t.co/G2HyAuLEGy #lymsm

[Uriel Suárez @UsuarezMD]

Hodgkin lymphoma: EHA Clinical Practice Guidelines for diagnosis, treatment, and follow‐up - Eichenauer - 2026 - HemaSphere - Wiley Online Library https://t.co/ghB3RXagBT

[Uriel Suárez @UsuarezMD]

Radiotherapy for indolent primary cutaneous B-cell lymphoma: an international multicenter ILROG analysis | Blood | American Society of Hematology https://t.co/JpRjtROpqL

[Ahmed Kotb @AhmedKo45911157]

DLBCL treatment is becoming biology-driven:
🔹GCB → R-CHOP
🔹ABC → Pola-R-CHP
🔹Double-hit → DA-R-EPOCH

Relapse <12 months: CAR-T preferred
Relapse >12 months: Salvage + Auto-SCT

Future: CAR-T, bispecific antibodies, ADCs, and personalized sequencing

https://t.co/6KLh1cyJ8b

[Updates in Medicine @medic_updates]

Anticoagulation Reversal in 2026: What Every Clinician Should Know.

[Dr Rupam Manna MD @DrRupamOncology]

Recurrent sinonasal carcinoma after definitive chemoradiation is one of the most challenging scenarios in head & neck oncology.
This practical infographic outlines a clear, step-by-step clinical approach:
✅ Confirming the exact histology (SNUC, SMARCB1-deficient, NUT carcinoma, SCC & other key entities)
✅ Defining the pattern of recurrence (local / orbital / distant)
✅ Assessing feasibility of salvage surgery
✅ Histology-specific systemic therapy options
✅ Role of re-irradiation & molecular profiling in recurrent disease
Key takeaway: Histological re-classification can completely change management. Many “poorly differentiated carcinomas” turn out to be distinct entities requiring different strategies.
High-yield resource for medical oncology residents, fellows & practicing head & neck oncologists.
Save this for your next recurrent sinonasal case 👇
#SinonasalCarcinoma #HeadAndNeckCancer #HNSCC #MedicalOncology #OncologyEducation #DrRupamManna

[Vincent Rajkumar @VincentRK]

Just out: Treatment of diffuse large cell lymphoma.

Current Treatment Algorithm @BloodCancerJnl by Steve Ansell and Greg Nowakowski #OpenAccess

https://t.co/pxkmIbz3QC

[Dr. Chokri Ben Lamine @abouabdrahman0]

EHA2026 DLBCL Pearls — First-line journey 🧬🧫

🧬 R-CHOP changed DLBCL history
Since 2002, adding rituximab to CHOP improved response, EFS, and OS in elderly DLBCL without major added toxicity. Still, ~40% of patients are not cured with frontline therapy.

🔥 DLBCL is not one disease
Risk stratification remains essential:
IPI risk score 📊
Cell of origin: GCB vs ABC 🧬
High-grade biology: double-hit / triple-hit ⚠️

🧬 Cell of origin matters
ABC/non-GCB disease generally carries worse prognosis than GCB, and ABC biology appears more common in older patients in the presented dataset.

💊 Modern 1L options are evolving
For fit adults, current standards include R-CHOP and Pola-R-CHP in selected patients. POLARIX showed improved 2-year PFS with polatuzumab vedotin + R-CHP vs R-CHOP, with broadly comparable safety.

👴 Frailty changes the regimen
Older/frail patients may need adapted therapy:
R-mini-CHOP if >80 and no major cardiac dysfunction
Anthracycline-sparing approaches if cardiac dysfunction: R-CEOP / R-COMP / R-CVP / R-GemOx depending fitness and intent.

⚠️ Double-hit / triple-hit HGBCL
Young fit selected patients may need intensified regimens such as DA-EPOCH-R rather than routine R-CHOP, while unfit patients may still receive R-CHOP-based treatment depending tolerance and goals.

🎯 Main clinical message
The goal in frontline LBCL is simple but difficult: maximize cure rate without compromising safety.

🧠 Perfect MCQ
A 68-year-old fit patient with newly diagnosed advanced-stage DLBCL, IPI 3, normal cardiac function. Which is a current frontline option?
A. R-CHOP only; no alternatives
B. Pola-R-CHP or R-CHOP depending patient/risk/context
C. BTK inhibitor monotherapy
D. Observation

✅ Answer: B — Pola-R-CHP has become a frontline option for selected fit patients based on POLARIX, while R-CHOP remains a standard backbone.

#EHA2026 #DLBCL #Lymphoma #RCHOP #PolaRCHP #Bispecifics #Hematology #KFSHRC

[Ahmed Kotb @AhmedKo45911157]

2nd line 👍
R/R DLBCL

[Ahmed Kotb @AhmedKo45911157]

📌 #EHA26 First-Line LBCL

🔹 R-CHOP remains the backbone of therapy.
🔹 Pola-R-CHP for higher-risk advanced disease.
🔹 R-mini-CHOP for frail/elderly patients.
🔹 DA-EPOCH-R for selected double/triple-hit lymphomas.

🎯 Goal: maximize cure while maintaining safety.

[Benlazar S M A @smbenlazar]

Studies of novel combinations in IC ineligible AML patients #EHA26

[Ahmed Kotb @AhmedKo45911157]

🩸 The future of AML is in rational combinations for IC Ineligible population

🧬 Venetoclax-based regimens are being paired with IDH, FLT3, menin, CD47, and CD123-targeted therapies to further improve outcomes.

#EHA26 #AML #Leukemia #Venetoclax #PrecisionMedicine

[MV Chandrakanth @ChandrakanthMv]

🇮🇳 Practice-Changing ASCO 2026 Updates in Breast Cancer

🔹 OPTIMA
• PAM50 genomics can help identify patients who may safely avoid chemotherapy

🔹 IRIS-A
• Selected Stage IA HER2+ tumors (≤0.5 cm) may not require taxane-based therapy

🔹 SENOMAC
• Some patients with 1–2 positive sentinel nodes can avoid completion ALND

🔹 ER-Low Analysis
• ER-low (1–10%) disease may behave differently from conventional HR-positive breast cancer

🔹 PATHWAY
• Tamoxifen remains a valid endocrine backbone with CDK4/6 inhibition

📌 Overall ASCO 2026 Message:
• Less chemotherapy
• Less surgery
• More precision
• More individualized treatment

#ASCO2026 #BreastCancer #Oncology #MedTwitter #MVOnco

[Dr Rishabh Jain @DrRishabhOnco]

Does PD-L1 ≥50% always mean pembrolizumab alone? 🤔

This retrospective NSCLC study says: not necessarily.

👥 Advanced NSCLC, PD-L1 TPS ≥50%, EGFR/ALK negative
n=206
PC: pembro + chemo
PM: pembro alone

📊 Key results:
PFS: 12.37 vs 9.60 mo
HR 0.44, p<0.001

OS: NR vs 28.91 mo
HR 0.40, p=0.005

ORR: 61.7% vs 46.9%

🧠 My take:
For fit patients with high disease burden, chemo-IO may still be the stronger first-line option, even in PD-L1 high disease.

But this is retrospective. Selection bias matters. Prospective data remain key.

🔖 Save this for clinic discussions.

📖 Full paper in comment ⬇️

#LCSM #OncoTwitter #MedTwitter @OncoAlert @myesmo @esmo_open

[Enrique Grande @drenriquegrande]

⚡️ EV-302 at #ASCO26: 3.5-year follow-up confirms durable OS benefit with EV + pembrolizumab in la/mUC.

Median OS: 33.6 vs 15.9 months (HR 0.53). Among complete responders, 42-month OS >82%.

The standard of care holds — and deepens over time.

https://t.co/rqqkbVMGnk

@tompowles1 #BladderCancer

[Eric Topol @EricTopol]

The ramp up of cancer immunotherapy is remarkable. Now we're seeing vaccines achieve some cures or remissions in the most refractory cancers: pancreatic, melanoma, glioblastoma, renal, triple-negative breast cancer.
✓ out the new Ground Truths (link in profile)

[Muzaffar Qazilbash @Transplant_Doc]

Administration of IV iron therapy during acute infections was associated with improved 14- and 90-day survival #hematology @BloodPortfolio @CAMCHemOncIAM https://t.co/X7ad8vDvyl

[Dr Rupam Manna MD @DrRupamOncology]

💥 HOW GEMCITABINE + DOCETAXEL WORK IN SOFT TISSUE SARCOMA 💥

One of the most important chemotherapy combinations in: 🎯 Leiomyosarcoma 🎯 UPS 🎯 Angiosarcoma 🎯 Metastatic/Refractory STS

🧬 Gemcitabine ➡️ Damages DNA replication ➡️ Causes S-phase arrest ➡️ Creates genomic instability

🌿 Docetaxel ➡️ Freezes microtubules ➡️ Blocks mitosis (G2/M arrest) ➡️ Causes mitotic catastrophe

🔥 Together: ✅ DNA damage ✅ Cell-cycle arrest ✅ Apoptosis ✅ Chemosensitization ✅ Sequential multi-phase tumor killing

💡 Why sequence matters? Gemcitabine is usually given FIRST to sensitize sarcoma cells before docetaxel-mediated mitotic destruction.

This synergy is especially effective in leiomyosarcoma due to: ✔️ High proliferative activity ✔️ Genomic instability ✔️ Sensitivity to replication stress

📚 Understanding the molecular biology behind chemotherapy helps us understand WHY regimens work—not just WHAT we give.

#SoftTissueSarcoma #Leiomyosarcoma #Gemcitabine #Docetaxel #MedicalOncology #Sarcoma #CancerBiology #Chemotherapy #OncologyEducation #DrRupamManna #CancerConceptsExplained #OncologyLearning #MedEd #FOAMed #CancerResearch

[Mauricio Lema-Medina @OncoNerd]

Cárcinoma escamocelular de cabeza y cuello - parte III: carcinoma nasofaríngeo (conceptos básicos) - https://t.co/Y4grFWhs2M